Year: 2017
Type: review
Study design: Systematic Review
Abstract: PSP is a pathologically defined neurodegenerative tauopathy with a variety of clinical presentations including typical Richardson's syndrome and other variant PSP syndromes. A large body of neuroimaging research has been conducted over the past two decades, with many studies proposing different structural MRI and molecular PET/SPECT biomarkers for PSP. These include measures of brainstem, cortical and striatal atrophy, diffusion weighted and diffusion tensor imaging abnormalities, [18F] fluorodeoxyglucose PET hypometabolism, reductions in striatal dopamine imaging and, most recently, PET imaging with ligands that bind to tau. Our aim was to critically evaluate the degree to which structural and molecular neuroimaging metrics fulfill criteria for diagnostic biomarkers of PSP. We queried the PubMed, Cochrane, Medline, and PSYCInfo databases for original research articles published in English over the past 20 years using postmortem diagnosis or the NINDS-SPSP criteria as the diagnostic standard from 1996 to 2016. We define a five-level theoretical construct for the utility of neuroimaging biomarkers in PSP, with level 1 representing group-level findings, level 2 representing biomarkers with demonstrable individual-level diagnostic utility, level 3 representing biomarkers for early disease, level 4 representing surrogate biomarkers of PSP pathology, and level 5 representing definitive PSP biomarkers of PSP pathology. We discuss the degree to which each of the currently available biomarkers fit into this theoretical construct, consider the role of biomarkers in the diagnosis of Richardson's syndrome, variant PSP syndromes and autopsy confirmed PSP, and emphasize current shortfalls in the field. © 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Source: Movement Disorders
DOI: 10.1002/mds.27038
Authors: Jennifer L. Whitwell, Günter U. Höglinger, Angelo Antonini, Yvette Bordelon, Adam L. Boxer, Carlo Colosimo, Thilo van Eimeren, Lawrence I. Golbe, Jan Kassubek, Carolin Kurz, Irene Litvan, Alexander Pantelyat, Gil Rabinovici, Gesine Respondek, Axel Rominger, James B. Rowe, Maria Stamelou, Keith A. Josephs, for the Movement Disorder Society‐endorsed PSP Study Group
Institutions: Mayo Clinic, German Center for Neurodegenerative Diseases, Technical University of Munich, University of Padua, IRCCS San Camillo Hospital, University of California, Los Angeles, University of California, San Francisco, Azienda Ospedaliera S.Maria, University of Cologne, Rutgers, The State University of New Jersey, Universität Ulm, Ludwig-Maximilians-Universität München, University of California San Diego, Johns Hopkins University, University of Cambridge, Philipps University of Marburg, National and Kapodistrian University of Athens, Hygeia Hospital, University General Hospital Attikon
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,480
Funders: International Parkinson and Movement Disorder Society, CurePSP, Wellcome Trust, Deutsche Forschungsgemeinschaft, Deutsches Zentrum für Neurodegenerative Erkrankungen, National Institutes of Health, Medical Research Council, National Institute on Aging, National Heart, Lung, and Blood Institute, National Institute on Deafness and Other Communication Disorders, National Institute of Neurological Disorders and Stroke
Awards: UKDP: Integrated DEmentiA research environment (IDEA), G2418776583, Early Age-of-Onset AD: Clinical Heterogeneity and Network Degeneration, Effects of chronic inflammation on brain structure and function, UCSD Alzheimer's Disease Research Center P50, Restoring brain function: from cortical microcircuits to complex behaviours in neurodegenerative disease., Johns Hopkins Medicine Biomarker Discovery in Parkinson's Disease, T35 Short Term Research Training Grant, G5450248422, Understanding the role of TDP-43 in Alzheimer’s disease and FTLD, Longitudinal Multi-modal Imaging in Progressive Supranuclear Palsy Syndromes, Innovative Technologies for Stratified and Experimental Medicine, CTE and Posttraumatic Neurodegeneration: Neuropathology and Ex Vivo Imaging, The Frontotemporal Lobar Degeneration Clinical Research Consortium, The Four Repeat Tauopathy Neuroimaging Initiative, Assessment of hyperphosphorylated tau PET binding in primary progressive aphasia, Frontotemporal Dementia: Genes, Images, and Emotions, Molecular and structural imaging in atypical Alzheimer's disease: a longitudinal study, Longitudinal multi-modality imaging in non-fluent/agrammatic primary progressive aphasia, New Approaches to Dementia Heterogeneity
OpenAlex ID: W2612001459
